Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUF8JZ)

• Drug Name: veratridine Drug Info
• Synonyms: veratrine; 3-veratroylveracevine

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 6280
  ChEBI ID: CHEBI:28051
  CAS Number: CAS 71-62-5
  TTD Drug ID: DMUF8JZ
  VARIDT Drug ID: DR01020

Molecule-Related Drug Atlas

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.4 (SCN4A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lanperisone	DM4EGPN	Musculoskeletal disorder	FA00-FC0Z	Phase 3	[10]
SIPATRIGINE	DMMQ4GC	Neurological disorder	6B60	Discontinued in Phase 2	[11]
V-102862	DMR2EUV	N. A.	N. A.	Discontinued in Phase 1	[12]
batrachotoxin	DMYH9SU	Discovery agent	N.A.	Investigative	[5]
BW-202W92	DMFKXMT	Discovery agent	N.A.	Investigative	[11]
CCNCSSKWCRDHSRCC	DMBGHTW	Discovery agent	N.A.	Investigative	[13]
CCNCSSKWCRAHSRCC	DM96YR2	Discovery agent	N.A.	Investigative	[13]
CCACSSKWCRDHSRCC	DMSE20Y	Discovery agent	N.A.	Investigative	[13]
CCNCASKWCRDHSRCC	DMRFA5O	Discovery agent	N.A.	Investigative	[13]
ZNCCNCSSKWCRDHSRCC	DMY2V37	Discovery agent	N.A.	Investigative	[13]

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.7 (SCN9A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
XEN-402	DMR69CG	Osteoarthritis	FA00-FA05	Phase 2	[14]
PF-05089771	DMD74BJ	Chronic pain	MG30	Phase 2	[15]
BIIB074	DMLV1ET	Bipolar disorder	6A60	Phase 2	[16]
DSP-2230	DM0WTMD	Neuropathic pain	8E43.0	Phase 1	[16]
BIIB095	DMUC6EP	Pain	MG30-MG3Z	Phase 1	[16]
GDC0310	DMUNFEP	Chronic pain	MG30	Phase 1	[17]
DSP-3905	DMYHU24	Neuropathic pain	8E43.0	Phase 1	[16]
PF-05241328	DM2NTBL	Pain	MG30-MG3Z	Phase 1	[18]
DWJ-208	DMQKDJZ	Cancer related pain	MG30	Phase 1	[16]
RG7893	DM1R4MQ	Pain	MG30-MG3Z	Phase 1	[19]

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.2 (SCN2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
batrachotoxin	DMYH9SU	Discovery agent	N.A.	Investigative	[20]
aconitine	DMFOZ60	Discovery agent	N.A.	Investigative	[3]

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.5 (SCN5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mephenytoin	DM5UGDK	Epilepsy	8A60-8A68	Approved	[21]
Mexiletine	DMCTE9R	Ventricular tachycardia	BC71	Approved	[22]
Fosphenytoin	DMOX3LB	Epilepsy	8A60-8A68	Approved	[21]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[22]
LOMERIZINE	DME0TC8	Migraine	8A80	Approved	[23]
Tetrodotoxin	DMWMPRG	Bacterial infection	1A00-1C4Z	Approved	[24]
Dyclonine	DMU6OFP	Pain	MG30-MG3Z	Approved	[25]
Moricizine	DMOMBJW	Arrhythmia	BC9Z	Approved	[26]
Ethotoin	DMXWOCP	Complex partial seizure	8A68.0	Approved	[27]
Prilocaine	DMI7DZ2	Pain	MG30-MG3Z	Approved	[25]

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.8 (SCN10A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rilpivirine	DMJ0QOW	Human immunodeficiency virus infection	1C62	Approved	[28]
Ropivacaine	DMSPJG2	Anaesthesia	9A78.6	Approved	[29]
Bupivacaine	DM4PRFC	Anaesthesia	9A78.6	Approved	[29]
Tiapride	DMN6CAG	Alcohol dependence	6C40.2	Approved	[30]
Tetracaine	DM9J6C2	Spinal anesthesia	MB40.3	Approved	[31]
Proparacaine	DMLS39E	Anaesthesia	9A78.6	Approved	[29]
Conatumumab	DM2UOSN	Colorectal cancer	2B91.Z	Phase 2	[32]
VX-150	DMGDB21	Neuropathic pain	8E43.0	Phase 2	[17]
DSP-2230	DM0WTMD	Neuropathic pain	8E43.0	Phase 1	[16]
PF-01247324	DM93LMS	Pain	MG30-MG3Z	Phase 1	[33]

Drug(s) Targeting SCN1A messenger RNA (SCN1A mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
US9694002, 495	DMV1OR0	N. A.	N. A.	Patented	[34]
US9694002, 59	DM804T5	N. A.	N. A.	Patented	[34]
US9694002, 129	DMMCNVO	N. A.	N. A.	Patented	[34]
batrachotoxin	DMYH9SU	Discovery agent	N.A.	Investigative	[2]

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.6 (SCN8A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NBI-921352	DMTTW9V	Epileptic encephalopathy	8A62	Phase 2	[35]
XEN901	DMRP9YF	Epilepsy	8A60-8A68	Phase 1	[16]
PRAX-330	DMHIS3M	Epilepsy	8A60-8A68	Phase 1	[17]
batrachotoxin	DMYH9SU	Discovery agent	N.A.	Investigative	[7]
4,9-anhydro-tetrodotoxin	DMEKI1B	Discovery agent	N.A.	Investigative	[36]

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.3 (SCN3A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LIDOFLAZINE	DMV23GL	Angina pectoris	BA40	Approved	[37]
Aryl carboxamide derivative 1	DMTZRCW	N. A.	N. A.	Patented	[38]
Aryl carboxamide derivative 2	DM146TA	N. A.	N. A.	Patented	[38]
Pyrimidine derivative 1	DMN9VQM	N. A.	N. A.	Patented	[38]
Pyrrolo-pyridinone derivative 6	DMXGNP8	N. A.	N. A.	Patented	[38]
Pyrrolo-pyridinone derivative 5	DMK2FSY	N. A.	N. A.	Patented	[38]
SIPATRIGINE	DMMQ4GC	Neurological disorder	6B60	Discontinued in Phase 2	[39]
U-92032	DMTYO3P	N. A.	N. A.	Terminated	[40]
PD-85639	DMNUKB4	N. A.	N. A.	Terminated	[37]
batrachotoxin	DMYH9SU	Discovery agent	N.A.	Investigative	[4]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
SCN1A messenger RNA (SCN1A mRNA)	TTANOZH	SCN1A_HUMAN	Activator	[2]
Voltage-gated sodium channel alpha Nav1.2 (SCN2A)	TTLJTUF	SCN2A_HUMAN	Activator	[3]
Voltage-gated sodium channel alpha Nav1.3 (SCN3A)	TTAXZ0K	SCN3A_HUMAN	Activator	[4]
Voltage-gated sodium channel alpha Nav1.4 (SCN4A)	TT84DRB	SCN4A_HUMAN	Activator	[5]
Voltage-gated sodium channel alpha Nav1.5 (SCN5A)	TTZOVE0	SCN5A_HUMAN	Activator	[6]
Voltage-gated sodium channel alpha Nav1.6 (SCN8A)	TT54ERL	SCN8A_HUMAN	Activator	[7]
Voltage-gated sodium channel alpha Nav1.7 (SCN9A)	TT4G2JS	SCN9A_HUMAN	Activator	[8]
Voltage-gated sodium channel alpha Nav1.8 (SCN10A)	TT90XZ8	SCNAA_HUMAN	Activator	[9]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2626).
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 578).
• [3] Binding of batrachotoxinin A 20-alpha-benzoate to a receptor site associated with sodium channels in synaptic nerve ending particles. J Biol Chem. 1981 Sep 10;256(17):8922-7.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 580).
• [5] Point mutations in segment I-S6 render voltage-gated Na+ channels resistant to batrachotoxin. Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2653-8.
• [6] Sodium channel comodification with full activator reveals veratridine reaction dynamics. Mol Pharmacol. 1990 Feb;37(2):144-8.
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 583).
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 584).
• [9] A comparison of the effects of veratridine on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels in isolated rat dorsal root ganglio... Pflugers Arch. 2008 Feb;455(5):929-38.
• [10] Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46.
• [11] Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones. J Med Chem. 2009 May 14;52(9):2694-707.
• [12] 3-(4-phenoxyphenyl)pyrazoles: a novel class of sodium channel blockers. J Med Chem. 2004 Mar 11;47(6):1547-52.
• [13] Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J Biol Chem. 2007 Oct 19;282(42):30699-706.
• [14] Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain. 2012 Jan;153(1):80-5.
• [15] Primary erythromelalgia: a review. Orphanet J Rare Dis. 2015 Sep 30;10:127.
• [16] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [17] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [18] Recent progress in sodium channel modulators for pain. Bioorg Med Chem Lett. 2014 Aug 15;24(16):3690-9.
• [19] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041740)
• [20] Interaction of batrachotoxin with the local anesthetic receptor site in transmembrane segment IVS6 of the voltage-gated sodium channel. Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13947-52.
• [21] Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
• [22] Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9.
• [23] Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
• [24] Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade. Eur J Pharmacol. 2002 Oct 4;452(2):175-81.
• [25] Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12.
• [26] From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. Am J Cardiol. 1996 Aug 29;78(4A):28-33.
• [27] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [28] Structures of muO-conotoxins from Conus marmoreus. I nhibitors of tetrodotoxin (TTX)-sensitive and TTX-resistant sodium channels in mammalian senso... J Biol Chem. 2004 Jun 11;279(24):25774-82.
• [29] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [30] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [31] Heterologous expression and functional analysis of rat Nav1.8 (SNS) voltage-gated sodium channels in the dorsal root ganglion neuroblastoma cell line ND7-23. Neuropharmacology. 2004 Mar;46(3):425-38.
• [32] Pathobiology of visceral pain: molecular mechanisms and therapeutic implications. II. Genetic approaches to pain therapy. Am J Physiol Gastrointest Liver Physiol. 2000 Apr;278(4):G507-12.
• [33] Oral Administration of PF-01247324, a Subtype-Selective Nav1.8 Blocker, Reverses Cerebellar Deficits in a Mouse Model of Multiple Sclerosis. PLoS One. 2015; 10(3): e0119067.
• [34] Substituted benzamides and methods of use thereof. US9694002.
• [35] Clinical pipeline report, company report or official report of Neurocrine Biosciences
• [36] The TTX metabolite 4,9-anhydro-TTX is a highly specific blocker of the Na(v1.6) voltage-dependent sodium channel. Am J Physiol Cell Physiol. 2007 Aug;293(2):C783-9.
• [37] Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74.
• [38] Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
• [39] Synthesis and structure-activity relationships of 6,7-benzomorphan derivatives as use-dependent sodium channel blockers for the treatment of stroke. J Med Chem. 2002 Aug 15;45(17):3755-64.
• [40] Discovery of (2S)-1-(4-amino-2,3,5- trimethylphenoxy)-3-[4-[4-(4- fluorobenzyl)phenyl]-1-piperazinyl]-2-propanol dimethanesulfonate (SUN N8075): a ... J Med Chem. 2000 Sep 7;43(18):3372-6.